Ascensia Diabetes Care has expanded its partnership with Insulet (NSDQ:PODD) to include a global commercial deal. The two companies inked a world-wide development agreement in June last year to connect Ascensia’s Contour Next One blood glucose monitor with Insulet’s next-gen Omnipod system, Omnipod Dash. Get the full story at our sister site, Drug Delivery Business News.
The Centers for Medicare and Medicaid Services issued guidance today noting that Insulet‘s (NSDQ:PODD) Omnipod tubeless insulin delivery device can be covered by the Medicare Part D prescription drug program. The Billerica, Mass.-based company estimated that its latest reimbursement win extends access to the Omnipod system to 450,000 people with Type I diabetes across the U.S. […]
Updated Jan. 5, 2018 Among the most successful medical device companies of 2017, there were two themes: innovation and breadth of services. That was the major takeaway of an MDO analysis of the stock performance of the 100 largest publicly traded medtech companies in the world. What does innovation mean? Think Align Technology (Nasdaq:ALGN) and […]
Among the world’s largest medtech companies, these 10 spent the largest portion of their budgets on research and development. So what have they produced? Every year, Medical Design & Outsourcing pulls financial regulatory filings and reaches out to major, companies in some cases to create a list of the 100 largest medical device companies in […]
Insulet (NSDQ:PODD) up-sized the private placement that it announced yesterday, citing strong investor demand. The Billerica, Mass.-based company said today it plans to offer $350 million in convertible senior notes due in 2024, up from $300 million. Get the full story at our sister site, Drug Delivery Business News.
Insulet (NSDQ:PODD) said today that it plans to offer $300 million in convertible senior notes due in 2024 as part of a private placement. The Billerica, Mass.-based company is also slated to give initial purchasers an option to buy an additional $45 million in notes. Get the full story at our sister site, Drug Delivery Business […]
Shares in Insulet (NSDQ:PODD) soared today after the medical device maker topped sales expectations on Wall Street with its third quarter results. The Billerica, Mass-based company posted a net loss of -$2.2 million on sales of $121.8 million for the 3 months ended Sept. 30, for bottom-line growth of 38% on sales growth of 28% compared with […]
At the 7th annual Partnership Opportunities in Drug Delivery event, presented by The Conference Forum, device companies gathered to tout their drug-delivery technologies and learn from each other’s mistakes and successes. Among them were needle-free injectors, patch pumps, auto-injectors and other novel delivery devices. Moderated by Pfizer‘s (NYSE:PFE) senior director of device strategy, Mathias Romacker, companies including Insulet (NSDQ:PODD), West Pharmaceutical […]
Insulet (NSDQ:PODD) and Dexcom (NSDQ:DXCM) yesterday floated a joint promotion aimed at luring users of the Animas insulin pump after Johnson & Johnson (NYSE:JNJ) bails out of the insulin pump biz. The companies are hoping to chip off a piece of the diabetes market from Medtronic (NYSE:MDT), to which J&J has offered to help some 90,000 Animas patients transfer (J&J is also evaluating another […]
Insulet (NSDQ:PODD) shareholder Frank Carnazza filed a derivative suit against the Billerica, Mass-based company last week in a Massachusetts federal court, alleging that Insulet misrepresented the success of its OmniPod Eros roll-out in 2013, which eventually caused the shares in the company to plummet. Carnazza named a number of former and current executives in the suit, […]
Just days after Johnson & Johnson (NYSE:JNJ) revealed that it plans to shut down its 410-worker Animas insulin pump subsidiary, Insulet (NSDQ:PODD) said it would offer existing Animas insulin pump users a free trial of the company’s Omnipod system. Insulet’s Welcome Program includes a free Omnipod tubeless insulin delivery system, built-in blood glucose meter and 30 days of supplies […]